Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
AZD-0754 by AstraZeneca for Metastatic Castration-Resistant Prostate Cancer (mCRPC): Likelihood of Approval
AZD-0754 is under clinical development by AstraZeneca and currently in Phase II for Metastatic Castration-Resistant Prostate Cancer (mCRPC). According to...